Phase I/II Study of Combination oral JAK2 tyrosine kinase inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) therapy in patients with Myelofibrosis
ID Number 12-1225Principal Investigator(s)
John O. Mascarenhas
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out if the drug combination of panobinostat and ruxolitinib is safe and has beneficial effects in people who have primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring.
Over 200 healthy subjects and 600 patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) have been treated with ruxolitinib in other clinical trials. In all of those trials, ruxolitinib has been given at several different dose levels. To date, over 1300 patients have been treated with panobinostat capsules in clinical trials. In all of those trials panobinostat has been given at several different dose levels, including 3 times per week, every week and every other week.
The purpose of this study is to determine how well and how safely the study medications work and how well the combination of study medications is tolerated at different dose levels in patients with your condition of PMF, PPV-MF or PET-MF.
Recruiting Patients: Yes